嵌合抗原受体（CAR）T 细胞治疗后复发/难治性非霍奇金淋巴瘤采用挽救性放疗的早期经验。
Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy.
机构信息
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Center for Cell Engineering and Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
出版信息
Br J Haematol. 2020 Jul;190(1):45-51. doi: 10.1111/bjh.16541. Epub 2020 Mar 5.
Abstract
Radiotherapy is potentially an important salvage strategy post-chimeric antigen receptor T cell therapy (CART), but limited data exist. We reviewed 14 patients treated with salvage radiation post-CART progression (SRT). Most received SRT for first post-CART relapse (71%) to sites previously PET-avid pre-CART (79%). Median overall survival (OS) post-SRT was 10 months. Post-SRT, six localized relapses achieved 100% response (3 = complete, 3 = partial), with improved freedom from subsequent relapse (P = 0·001) and OS (P = 0·004) compared to advanced stage relapses. Three were bridged to allogeneic transplantation; at analysis, all were alive/NED. SRT has diverse utility and can integrate with novel agents or transplantation to attempt durable remissions.
摘要
放疗是嵌合抗原受体 T 细胞疗法（CART）后一种有潜力的重要挽救策略，但相关数据有限。我们回顾了 14 例接受 CART 进展后挽救性放疗（SRT）治疗的患者。大多数患者因首次 CART 复发（71%）至先前 CART 前 PET 阳性部位而接受 SRT（79%）。SRT 后中位总生存期（OS）为 10 个月。SRT 后，6 例局限性复发达到 100%缓解（3 例完全缓解，3 例部分缓解），与晚期复发相比，无后续复发（P=0·001）和 OS（P=0·004）均得到改善。3 例患者接受异基因移植桥接治疗；在分析时，所有患者均存活/无疾病。SRT 具有多种用途，可与新的药物或移植相结合，以尝试持久缓解。
相似文献
1
Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy.
Br J Haematol. 2020 Jul;190(1):45-51. doi: 10.1111/bjh.16541. Epub 2020 Mar 5.
2
Incorporating radiation with anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory non-Hodgkin lymphoma: A multicenter consensus approach.
Am J Hematol. 2024 Jan;99(1):124-134. doi: 10.1002/ajh.27155. Epub 2023 Nov 11.
3
Assessment of Salvage Regimens Post-Chimeric Antigen Receptor T Cell Therapy for Patients with Diffuse Large B Cell Lymphoma.
Transplant Cell Ther. 2022 Jun;28(6):342.e1-342.e5. doi: 10.1016/j.jtct.2022.02.021. Epub 2022 Mar 4.
4
Salvage radiotherapy for relapsed/refractory non-Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy.
Clin Transl Radiat Oncol. 2023 Jan 20;39:100587. doi: 10.1016/j.ctro.2023.100587. eCollection 2023 Mar.
5
Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure.
Transplant Cell Ther. 2023 Sep;29(9):574.e1-574.e10. doi: 10.1016/j.jtct.2023.06.019. Epub 2023 Jun 30.
6
Don't Put the CART Before the Horse: The Role of Radiation Therapy in Peri-CAR T-cell Therapy for Aggressive B-cell Non-Hodgkin Lymphoma.
Int J Radiat Oncol Biol Phys. 2023 Aug 1;116(5):999-1007. doi: 10.1016/j.ijrobp.2022.12.017. Epub 2022 Dec 21.
7
ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Diffuse Large B-cell Lymphoma after Failure of Chimeric Antigen Receptor T Cell Therapy (CAR-T) Therapy.
Transplant Cell Ther. 2022 Sep;28(9):523-529. doi: 10.1016/j.jtct.2022.05.043. Epub 2022 Jun 6.
8
Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.
Am J Hematol. 2021 Jun 1;96(6):671-679. doi: 10.1002/ajh.26160. Epub 2021 Mar 29.
9
[Efficacy and safety of CD19 chimeric antigen receptor T cells for the treatment of 22 patients with B-cell lymphoma].
Zhonghua Xue Ye Xue Za Zhi. 2019 Apr 14;40(4):276-280. doi: 10.3760/cma.j.issn.0253-2727.2019.04.003.
10
The Current and Future Role of Radiation Therapy in the Era of CAR T-cell Salvage.
Br J Radiol. 2021 Nov 1;94(1127):20210098. doi: 10.1259/bjr.20210098. Epub 2021 Aug 10.
引用本文的文献
1
CAR T-Cell Therapies for Patients With Relapsed and Refractory Aggressive Lymphomas: Real-World Experiences From a Single Center on the Use of Radiotherapy.
Hematol Oncol. 2025 Sep;43(5):e70124. doi: 10.1002/hon.70124.
2
The Role of Radiotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Post-CAR-T Therapy: A Systematic Literature Review.
Technol Cancer Res Treat. 2025 Jan-Dec;24:15330338251351065. doi: 10.1177/15330338251351065. Epub 2025 Jun 18.
3
[Radiotherapy of non-Hodgkin lymphoma-discussion of modern treatment concepts and innovations].
Radiologie (Heidelb). 2025 Jun 11. doi: 10.1007/s00117-025-01477-3.
4
Role of Radiation in Combination With CD30-Directed Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Hodgkin Lymphoma.
Adv Radiat Oncol. 2023 Dec 23;9(4):101428. doi: 10.1016/j.adro.2023.101428. eCollection 2024 Apr.
5
Treatment strategies for relapse after CAR T-cell therapy in B cell lymphoma.
Front Pediatr. 2024 Jan 12;11:1305657. doi: 10.3389/fped.2023.1305657. eCollection 2023.
6
Hypofractionated radiotherapy for refractory or relapsed aggressive B-cell lymphoma in the rituximab era.
BMC Cancer. 2024 Jan 13;24(1):72. doi: 10.1186/s12885-024-11837-2.
7
Management of aggressive lymphoma after CAR T-cell therapy failure.
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):364-369. doi: 10.1182/hematology.2023000437.
8
The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors.
Biomark Res. 2023 Nov 28;11(1):103. doi: 10.1186/s40364-023-00537-x.
9
Application of interim PET-CT in first-line treatment decision-making for lymphoma.
J Zhejiang Univ Sci B. 2023 Oct 15;24(10):905-921. doi: 10.1631/jzus.B2200644.
10
The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma.
Exp Hematol Oncol. 2023 Aug 14;12(1):72. doi: 10.1186/s40164-023-00432-z.
本文引用的文献
1
CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma.
Blood. 2019 Aug 15;134(7):626-635. doi: 10.1182/blood.2018883421. Epub 2019 Jul 1.
2
Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma.
Int J Radiat Oncol Biol Phys. 2019 Dec 1;105(5):1012-1021. doi: 10.1016/j.ijrobp.2019.05.065. Epub 2019 Jun 5.
3
BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy.
Cancer Immunol Res. 2019 Jul;7(7):1047-1053. doi: 10.1158/2326-6066.CIR-18-0551. Epub 2019 May 21.
4
Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy.
Am J Hematol. 2019 Aug;94(8):E209-E213. doi: 10.1002/ajh.25505. Epub 2019 May 21.
5
Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation.
Front Oncol. 2018 Dec 13;8:612. doi: 10.3389/fonc.2018.00612. eCollection 2018.
6
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.
7
Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape.
Mol Ther. 2018 Nov 7;26(11):2542-2552. doi: 10.1016/j.ymthe.2018.09.008. Epub 2018 Sep 13.
8
The promise of CAR T-cell therapy in aggressive B-cell lymphoma.
Best Pract Res Clin Haematol. 2018 Sep;31(3):293-298. doi: 10.1016/j.beha.2018.07.011. Epub 2018 Aug 1.
9
The influence of radiation in the context of developing combination immunotherapies in cancer.
Ther Adv Vaccines Immunother. 2017 Dec;5(6):115-122. doi: 10.1177/2051013617750561. Epub 2018 Jan 24.
10
Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group.
Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):652-669. doi: 10.1016/j.ijrobp.2017.12.005.
Zotero 插件